Overview

Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome

Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
This study aims to explore the clinical and immunological efficacy of tofacitinib on primary Sjögren's Syndrome
Phase:
Phase 2
Details
Lead Sponsor:
Peking University People's Hospital
Treatments:
Tofacitinib